These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

248 related articles for article (PubMed ID: 6224623)

  • 41. Intermittent administration of inhaled tobramycin in patients with cystic fibrosis. Cystic Fibrosis Inhaled Tobramycin Study Group.
    Ramsey BW; Pepe MS; Quan JM; Otto KL; Montgomery AB; Williams-Warren J; Vasiljev-K M; Borowitz D; Bowman CM; Marshall BC; Marshall S; Smith AL
    N Engl J Med; 1999 Jan; 340(1):23-30. PubMed ID: 9878641
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Evidence for the efficacy of aztreonam for inhalation solution in the management of Pseudomonas aeruginosa in patients with cystic fibrosis.
    Hansen C; Skov M
    Ther Adv Respir Dis; 2015 Feb; 9(1):16-21. PubMed ID: 25471692
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Resistance to tobramycin and colistin in isolates of Pseudomonas aeruginosa from chronically colonized patients with cystic fibrosis under antimicrobial treatment.
    Valenza G; Radike K; Schoen C; Horn S; Oesterlein A; Frosch M; Abele-Horn M; Hebestreit H
    Scand J Infect Dis; 2010 Dec; 42(11-12):885-9. PubMed ID: 20735333
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Antimicrobial efficacy of tobramycin polymeric nanoparticles for Pseudomonas aeruginosa infections in cystic fibrosis: formulation, characterisation and functionalisation with dornase alfa (DNase).
    Deacon J; Abdelghany SM; Quinn DJ; Schmid D; Megaw J; Donnelly RF; Jones DS; Kissenpfennig A; Elborn JS; Gilmore BF; Taggart CC; Scott CJ
    J Control Release; 2015 Jan; 198():55-61. PubMed ID: 25481442
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [TOBI Podhaler for treating chronic Pseudomonas aeruginosa infection in cystic fibrosis patients].
    Pierart F
    Rev Med Liege; 2013 Sep; 68(9):486-8. PubMed ID: 24180205
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Eradication of Pseudomonas aeruginosa in an adult patient with cystic fibrosis.
    Hayes D; Feola DJ; Murphy BS; Kuhn RJ; Davis GA
    Am J Health Syst Pharm; 2011 Feb; 68(4):319-22. PubMed ID: 21289326
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Polyanion-tobramycin nanocomplexes into functional microparticles for the treatment of Pseudomonas aeruginosa infections in cystic fibrosis.
    Craparo EF; Porsio B; Schillaci D; Cusimano MG; Spigolon D; Giammona G; Cavallaro G
    Nanomedicine (Lond); 2017 Jan; 12(1):25-42. PubMed ID: 27879162
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Antimicrobial activity of fosfomycin and tobramycin in combination against cystic fibrosis pathogens under aerobic and anaerobic conditions.
    McCaughey G; McKevitt M; Elborn JS; Tunney MM
    J Cyst Fibros; 2012 May; 11(3):163-72. PubMed ID: 22138067
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Tobramycin inhalation powder in cystic fibrosis patients: response by age group.
    Geller DE; Nasr SZ; Piggott S; He E; Angyalosi G; Higgins M
    Respir Care; 2014 Mar; 59(3):388-98. PubMed ID: 23983274
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Azlocillin in cystic fibrosis.
    Malmborg AS; Alfredsson H; Strandvik B
    Isr J Med Sci; 1983 Nov; 19(11):1001-3. PubMed ID: 6662681
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The emergence of resistance to beta-lactam antibiotics during treatment of Pseudomonas aeruginosa lower respiratory tract infections: is combination therapy the solution?
    Nichols L; Maki DG
    Chemioterapia; 1985 Feb; 4(1):102-9. PubMed ID: 3986938
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Ceftazidime alone and in combination in patients with cystic fibrosis: lack of efficacy in treatment of severe respiratory infections caused by Pseudomonas cepacia.
    Gold R; Jin E; Levison H; Isles A; Fleming PC
    J Antimicrob Chemother; 1983 Jul; 12 Suppl A():331-6. PubMed ID: 6352638
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Challenges with current inhaled treatments for chronic Pseudomonas aeruginosa infection in patients with cystic fibrosis.
    Greally P; Whitaker P; Peckham D
    Curr Med Res Opin; 2012 Jun; 28(6):1059-67. PubMed ID: 22401602
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Colistin-tobramycin combinations are superior to monotherapy concerning the killing of biofilm Pseudomonas aeruginosa.
    Herrmann G; Yang L; Wu H; Song Z; Wang H; Høiby N; Ulrich M; Molin S; Riethmüller J; Döring G
    J Infect Dis; 2010 Nov; 202(10):1585-92. PubMed ID: 20942647
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Therapeutic approaches to chronic cystic fibrosis respiratory infections with available, emerging aerosolized antibiotics.
    Ballmann M; Smyth A; Geller DE
    Respir Med; 2011 Dec; 105 Suppl 2():S2-8. PubMed ID: 22208546
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Tobramycin ototoxicity. Repeated courses of high dosage treatment in children with cystic fibrosis.
    Thomsen J; Friis B; Jensen K; Bak-Pedersen K; Larsen PK
    J Antimicrob Chemother; 1979 May; 5(3):257-60. PubMed ID: 479061
    [No Abstract]   [Full Text] [Related]  

  • 57. Spread of beta-lactam-resistant Pseudomonas aeruginosa in a cystic fibrosis clinic.
    Cheng K; Smyth RL; Govan JR; Doherty C; Winstanley C; Denning N; Heaf DP; van Saene H; Hart CA
    Lancet; 1996 Sep; 348(9028):639-42. PubMed ID: 8782753
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Nebulized tobramycin in the treatment of adult CF pulmonary exacerbations.
    Al-Aloul M; Nazareth D; Walshaw M
    J Aerosol Med Pulm Drug Deliv; 2014 Aug; 27(4):299-305. PubMed ID: 24219814
    [TBL] [Abstract][Full Text] [Related]  

  • 59. A network meta-analysis of the efficacy of inhaled antibiotics for chronic Pseudomonas infections in cystic fibrosis.
    Littlewood KJ; Higashi K; Jansen JP; Capkun-Niggli G; Balp MM; Doering G; Tiddens HA; Angyalosi G
    J Cyst Fibros; 2012 Sep; 11(5):419-26. PubMed ID: 22717535
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [Making antibiotic therapy easier to use. A welcome advance for those with cystic fibrosis].
    Sabourin G
    Perspect Infirm; 2011; 8(4):54-5. PubMed ID: 21812190
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.